Men's Health Radar

Researchers examined 50 prostate cancer consultations involving nine physicians across urology, medical oncology, and radiation oncology. They assessed how specifically clinicians discussed the cancer, prognosis, and treatment-related issues. The small, concentrated sample limits how widely the findings can be applied. The study assessed communication quality; it did not test whether a different conversation improves survival.

In a randomized, double-blind trial, 284 adults managing blood sugar with diet and exercise alone received one of three doses of an investigational oral small-molecule GLP-1 agonist or placebo for 32 weeks. The study reported improved HbA1c, while effects on body weight were modest. About one-third of participants were women, so the result is not specific to men. This investigational compound is a prescription pharmaceutical studied in clinical trials, not a dietary supplement ingredient or a general weight-loss solution.

A MESA cohort analysis included 6,531 men and women who had no cardiovascular disease at baseline, with a median 16.7 years of follow-up. Waist-to-height ratio and the inflammatory marker IL-6 statistically accounted for part of the association between ultra-processed food intake and later cardiovascular events. Diet and candidate mediators were measured at baseline and may have changed. As an observational analysis, it cannot establish a single causal pathway or test an anti-inflammatory supplement.

Researchers used shorts with embedded sensors to examine 7,684 sitting bouts in 84 adults from three cohorts. Thigh muscle activity approached its lowest levels after about 25 minutes of sitting. More frequent and more intense interruptions were associated with roughly five additional minutes of muscle activity per hour of sitting. The study measured muscle activation, not whether movement breaks prevent diabetes or build muscle.

A review examines how compounds produced by gut microbes might act as signals between the intestine and the testes. It brings together proposed biological mechanisms, much of them based on laboratory and preclinical evidence. The paper does not show that taking a probiotic raises testosterone or improves symptoms in men. Human intervention studies are needed before these mechanisms become treatment advice.

A critical narrative review looks at skeletal loading, low energy availability, and bone stress injury in triathletes. The authors say current research cannot reliably estimate the prevalence of relative energy deficiency in sport among male triathletes or define a sport-specific endocrine profile. It also does not support universal testosterone testing in this group. This is a review of evidence gaps, not a trial of a new treatment.

Researchers linked country-level prostate cancer mortality-to-incidence estimates from GLOBOCAN 2022 with 11 health-system indicators across 185 countries. An interpretable machine-learning model explored which indicators were associated with national patterns. This ecological analysis generates hypotheses about access and care capacity. It cannot predict an individual patient’s outcome or prove that changing one indicator improves survival.

A review examines repeated weight loss and regain in people with and without obesity. Its authors argue that weight cycling might contribute to obesity in some susceptible people who start out lean, but appears to have little effect on the progression of established obesity and related complications. This is an interpretation of varied prior evidence, not a new dieting trial. Cause and effect and individual differences remain difficult to resolve.

A modified Delphi panel brought together 14 people with lived experience and 11 professionals to shape an intervention for Black/African American men with criminal-legal-system involvement. The group reached consensus on 76 of 102 statements, including attention to blood pressure, smoking, diabetes, and cholesterol. The study identifies priorities for culturally tailored, coordinated care. It has not yet tested whether the proposed intervention improves cardiovascular outcomes.

A systematic review included ten studies of sprint athletes. Researchers used different tests of leg asymmetry and sprint performance, making results hard to combine into one clear recommendation. The current evidence does not establish a universal asymmetry correction that reliably makes athletes faster. This specialist finding is most relevant to coaches and competitive runners.

A study of 126 men compared alcohol-use groups on semen measures, oxidative-stress markers, and sperm DNA damage. Its group selection included fertile non-drinking controls and infertile men who drank, making pre-existing differences hard to separate from alcohol exposure. The associations cannot prove that alcohol caused infertility. Despite the paper’s question-form title, it does not establish a safe or unsafe threshold for an individual.

A review surveys gene editing, genetic-material delivery, and animal-model work for non-obstructive azoospermia. These approaches have preclinical proof of concept but face major questions about safety, delivery, and translation to patients. The publication does not announce an available human treatment. Current clinical options and experimental research must be clearly distinguished.

In April, the FDA invited manufacturers to discuss evidence for a possible new use of testosterone therapy in men with low libido and idiopathic hypogonadism. This is an invitation to seek review, not approval of a new indication. Any approval would still require evidence that benefits outweigh risks.

In June, HHS announced FDA requests to revise testosterone product labels after reviewing clinical evidence. The proposed changes address age-related hypogonadism, prostate cancer information and warnings about enlarged prostate. HHS says uncertainties remain about long-term prostate outcomes, so the announcement should not be read as proof that testosterone therapy is risk-free.

An analysis of the PROBASE study examined confirmatory PSA testing in men aged 45 to 55. Among those whose initial PSA was at least 3 ng/mL, 38% fell below that threshold on repeat testing. This supports confirmation before further investigation in the screening setting studied; a lower repeat result does not rule out cancer.

The randomized PRIMARY2 trial studied men with equivocal or non-suspicious prostate MRI findings and continuing clinical concern. Its diagnostic pathway used PSMA PET/CT to help decide who proceeded to biopsy and who could avoid an immediate biopsy. The trial addresses a selected higher-risk situation, not routine prostate screening.

The FDA approved Wegovy HD, a 7.2 mg semaglutide injection, for weight loss and long-term weight maintenance in eligible adults. The agency reported greater average weight reduction than with previously approved doses, alongside gastrointestinal adverse reactions and reports of altered skin sensation. The approval is not specific to men, and a higher dose is not automatically the right choice for an individual.

A retrospective study examined records of 215 men with testosterone measurements before and during incretin-based treatment. Testosterone levels rose on average as weight fell, with larger changes associated with greater weight loss. The observational design cannot establish that the medication directly caused the hormonal change or that prescribed testosterone treatment can be stopped.

The American Heart Association’s 2026 fact sheet estimates that 53.7% of U.S. men aged 20 or older had some form of cardiovascular disease in data from 2021 to 2023. It also reports a higher age-adjusted cardiovascular death rate for men than women in 2023. The publication is new, but its underlying observations come from earlier years and use a broad definition of cardiovascular disease.

A 2026 analysis estimated that nearly 23 million U.S. adults with high blood pressure and no known cardiovascular disease could qualify for medication under a 2025 guideline. About 9.7 million of those estimated to qualify were untreated in the study analysis. Participants included men and women, and blood pressure was measured at a single survey visit, so the estimates are not individual treatment decisions.

An American College of Sports Medicine position stand synthesized 137 systematic reviews covering more than 30,000 participants. Compared with no exercise, resistance training improved measures of strength, muscle size and physical function. The evidence covers healthy adults of both sexes and finds that several training approaches can be useful.

A review of 39 trials in healthy men aged 18 to 30 compared creatine findings across resistance-training and other training contexts. Gains in lean-body measures were reported with resistance training but were not significant in the non-resistance-training grouping. A correction appeared in May; its contents should be checked before publishing precise effect sizes or applying findings to older men.

FDA testing found undeclared amino tadalafil in DEEP, a product marketed for sexual enhancement, and the agency advised consumers not to buy or use it. FDA says the ingredient is similar to tadalafil and may interact with nitrates, potentially causing dangerously low blood pressure. This alert concerns the named product and does not show that every product in the category has the same composition.

The FDA advised consumers not to purchase or use MAXMAN Coffee after laboratory testing identified sildenafil and tadalafil absent from its label. The coffee format illustrates why a familiar-looking food or drink should not be assumed free of drug ingredients. FDA also cautions that it cannot test every potentially harmful product on the market.